0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure

Finlay A. McAlister, MD, MSc; Natasha Wiebe, MMath, PStat; Justin A. Ezekowitz, MD, MSc; Alexander A. Leung, MD; and Paul W. Armstrong, MD
[+] Article and Author Information

From the University of Alberta, Edmonton, Alberta, Canada.


Acknowledgment: The authors thank Jeff Bakal, PhD, PStat, for advice on the statistical analyses.

Grant Support: No external funding was received for the study. Dr. McAlister is supported by an Alberta Heritage Foundation for Medical Research Health Scholar Award and holds the Merck Frosst/Aventis Patient Health Management Chair at the University of Alberta. Dr. Ezekowitz is supported by the Canadian Institutes of Health Research.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Finlay A. McAlister, MD, MSc, University of Alberta Hospital, 2F1.21 Walter Mackenzie Health Sciences Centre, 8440 112 Street, Edmonton, Alberta T6G 2R7, Canada; e-mail, finlay.mcalister@ualberta.ca.

Current Author Addresses: Dr. McAlister: University of Alberta Hospital, 2F1.21 Walter Mackenzie Health Sciences Centre, 8440 112 Street, Edmonton, Alberta T6G 2R7, Canada.

Dr. Wiebe: University of Alberta, Research Transition Facility, Room 3048, 8308 114 Street, Edmonton, Alberta T6E 6L7 Canada.

Dr. Ezekowitz: Walter Mackenzie Health Sciences Centre, 2C2 Cardiology, 8440 112 Street, Edmonton, Alberta T6G 2B7, Canada.

Dr. Leung: 2F1 Walter Mackenzie Health Sciences Centre, University of Alberta Hospital, 8440 112 Street, Edmonton, Alberta T6G 2R7, Canada.

Dr. Armstrong: University of Alberta, VIGOUR Centre, 251 Medical Sciences Building, Edmonton, Alberta T6G 2H7, Canada.

Author Contributions: Conception and design: F.A. McAlister, N. Wiebe.

Analysis and interpretation of the data: F.A. McAlister, N. Wiebe, J.A. Ezekowitz, P.W. Armstrong.

Drafting of the article: F.A. McAlister, P.W. Armstrong.

Critical revision of the article for important intellectual content: F.A. McAlister, N. Wiebe, J.A. Ezekowitz, A.A. Leung, P.W. Armstrong.

Final approval of the article: F.A. McAlister, N. Wiebe, J.A. Ezekowitz, A.A. Leung, P.W. Armstrong.

Provision of study materials or patients: F.A. McAlister, J.A. Ezekowitz.

Statistical expertise: N. Wiebe.

Administrative, technical, or logistic support: F.A. McAlister.

Collection and assembly of data: F.A. McAlister, J.A. Ezekowitz, A.A. Leung.


Ann Intern Med. 2009;150(11):784-794. doi:10.7326/0003-4819-150-11-200906020-00006
Text Size: A A A

Background: Guidelines recommend that patients with heart failure receive β-blockers in doses used in the trials that have proven their efficacy. Although the adverse effects of β-blockade are dose-related, it is unclear whether the benefits are.

Purpose: To determine whether the survival benefits of β-blockade in heart failure are associated with the magnitude of heart rate reduction or the β-blocker dose.

Data Sources: MEDLINE, EMBASE, CINAHL, SIGLE, Web of Science, and the Cochrane Central Register of Controlled Trials, supplemented by hand-searches of bibliographies.

Study Selection: Randomized, placebo-controlled heart failure trials that reported all-cause mortality.

Data Extraction: Two reviewers independently extracted data on study characteristics, β-blocker dosing and heart rate reduction, and death.

Data Synthesis: The mean left ventricular ejection fraction in the 23 β-blocker trials ranged from 0.17 to 0.36, and more than 95% of the 19 209 patients had systolic dysfunction. The overall risk ratio for death was 0.76 (95% CI, 0.68 to 0.84); however, heterogeneity testing revealed moderate heterogeneity among trials (I2 = 30%), which was associated with the magnitude of heart rate reduction achieved within each trial (P for meta-regression = 0.006). For every heart rate reduction of 5 beats/min with β-blocker treatment, a commensurate 18% reduction (CI, 6% to 29%) in the risk for death occurred. No significant relationship between all-cause mortality and β-blocker dosing was observed (risk ratio for death, 0.74 [CI, 0.64 to 0.86]) in high-dose β-blocker trials vs. 0.78 [CI, 0.63 to 0.96] in low-dose β-blocker trials; P for meta-regression = 0.69).

Limitations: The analysis is based on aggregate data and resting heart rates. Few patients in these trials had bradycardia or diastolic dysfunction at baseline.

Conclusion: The magnitude of heart rate reduction is statistically significantly associated with the survival benefit of β-blockers in heart failure, whereas the dose of β-blocker is not.

Figures

Grahic Jump Location
Figure 2.
All-cause mortality in trials of 50 or more patients, by agent.

Trial acronyms are defined in Table 1. NA = not applicable; RR = risk ratio.

Grahic Jump Location
Grahic Jump Location
Figure 3.
All-cause mortality, by treatment-related HR reduction tertile.

Trial acronyms are defined in Table 1. HR = heart rate; RR = risk ratio.

Grahic Jump Location
Grahic Jump Location
Figure 4.
Meta-regression line for magnitude of heart rate reduction and risk ratio of all-cause mortality.

The mortality logarithm of relative risk is plotted against the reduction in heart rate. Circles are the observed estimates; size is based on the inverse of the SE of each trial. The 3 lines are the fitted and the upper and lower bounds of the 95% CIs.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)